Can1 and its role in mammalian infertility
OwnerColin E. Bishop, Alexander I. Agoulnik +1inventors
InventorsColin E. Bishop, Alexander I. Agoulnik, Qichao Zhu
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a Can1 mammalian sequence. Defects in this sequence result in aberrant migration and/or proliferation of primordial germ cells during embryonic development, leading to Sertoli Cell Only syndrome in males and Premature Ovarian Failure in females.
Claims50
As a composition of matter, a nucleic acid sequence of SEQ ID NO:1.
As a composition of matter, an amino acid sequence of SEQ ID NO:3.
A pharmaceutical composition comprising:
- an amino acid sequence of SEQ ID NO:3;
- and
- a pharmacologically acceptable carrier.
A method of treating infertility in a mammal, comprising the step of introducing a therapeutically effective amount of a Can1 nucleic acid sequence into said mammal.
A method of treating infertility in a mammal, comprising the step of introducing a therapeutically effective amount of a nucleic acid sequence of SEQ ID NO:1 into said mammal.
A method of treating infertility in a mammal, comprising the step of introducing a therapeutically effective amount of a nucleic acid sequence of SEQ ID NO:2 into said mammal.
A method of treating infertility in a mammal comprising the step of introducing into said mammal a therapeutically effective amount of an amino acid sequence of SEQ ID NO:3.
A method of treating infertility in a mammal comprising the step of introducing to said mammal a therapeutically effective amount of an amino acid sequence of SEQ ID NO:4.
A method of diagnosing infertility in a mammal, comprising the steps of:
- obtaining a biological sample from said mammal, wherein said sample includes a Can1 nucleic acid sequence;
- and
- assaying for a defect in said Can1 nucleic acid sequence.
A method of diagnosing infertility in a mammal, comprising the steps of:
- obtaining a biological sample from said mammal, wherein said sample includes a Can1 amino acid sequence;
- and
- assaying for a defect in said Can1 amino acid sequence.
A method of increasing the number of primordial germ cells in a mammal, comprising the step of introducing into said mammal a physiologically significant level of a Can1 nucleic acid sequence.
A method of increasing the number of primordial germ cells in a mammal, comprising the step of introducing into said mammal a physiologically significant level of a Can1 amino acid sequence.
A method of stimulating germ cell growth in a mammal, comprising the step of introducing into said mammal a physiologically effective level of a Can1 nucleic acid sequence.
A method of stimulating germ cell growth in a mammal, comprising the step of introducing into said mammal a physiologically effective level of a Can1 amino acid sequence.
A method of screening for an active compound for the treatment of infertility, comprising the steps of:
- obtaining an organism, wherein the genome of said organism includes a reporter sequence whose expression is controlled by a Can1 regulatory nucleic acid sequence;
- exposing a test agent to said organism;
- and
- measuring a change in said expression, wherein said change indicates said test agent is said active compound.
A method of screening in vitro for an active compound for the treatment of infertility, comprising the steps of:
- obtaining a cell, wherein said cell includes a nucleic acid sequence having a reporter sequence and wherein the expression of said reporter sequence is controlled by a Can1 regulatory nucleic acid sequence;
- exposing a test agent to said cell;
- and
- measuring a change in said expression, wherein said change indicates said test agent is said active compound.
A method of screening for a candidate substance for the treatment of infertility comprising the steps of:
- providing a cell lacking a functional Can1 amino acid sequence;
- contacting said cell with said candidate substance;
- and
- determining the effect of said candidate substance on said cell, wherein said effect on said cell is indicative said candidate substance treats infertility.
A transgenic non-human animal whose genome comprises a transgene encoding a Can1 amino acid sequence, wherein said transgene is under the control of an operably linked promoter active in eukaryotic cells.
A transgenic non-human animal comprising a genome with a heterozygous disruption of a nucleic acid encoding a Can1 polypeptide.
A transgenic non-human animal comprising a genome with a homozygous disruption of a nucleic acid encoding a Can1 polypeptide.
A monoclonal antibody that binds immunologically to a polypeptide comprising SEQ ID NO:3, or an antigenic fragment thereof.
A polyclonal antisera, antibodies of which bind immunologically to a polypeptide comprising SEQ ID NO:3, or an antigenic fragment thereof.
A monoclonal antibody that binds immunologically to a polypeptide comprising SEQ ID NO:4, or an antigenic fragment thereof.
A polyclonal antisera, antibodies of which bind immunologically to a polypeptide comprising SEQ ID NO:4, or an antigenic fragment thereof.
A method of screening for an active compound for infertility, comprising the steps of:
- introducing into a cell
- a first nucleic acid expressing a fused test peptide/DNA binding domain;
- and
- a second nucleic acid expressing a fused Can1 polypeptide/DNA activation domain;
- and
- assaying for an interaction between said test peptide and said Can1 polypeptide by measuring binding between said DNA binding domain and said DNA activation domain, wherein said interaction between said test peptide and said Can1 polypeptide indicates said test peptide is said active compound.
A method of treating an individual for premature ovarian failure, comprising the step of administering to said individual a nucleic acid sequence of SEQ ID NO:1.
A method of treating an individual for premature ovarian failure, comprising the step of administering to said individual a nucleic acid sequence of SEQ ID NO:2.
A method of treating an individual for premature ovarian failure, comprising the step of administering to said individual an amino acid sequence of SEQ ID NO:3.
A method of treating an individual for premature ovarian failure, comprising the step of administering to said individual an amino acid sequence of SEQ ID NO:4.
A method of treating an individual for Sertoli Cell only syndrome, comprising the step of administering to said individual a nucleic acid sequence of SEQ ID NO:1.
A method of treating an individual for Sertoli Cell only syndrome, comprising the step of administering to said individual a nucleic acid sequence of SEQ ID NO:2.
A method of treating an individual for Sertoli Cell only syndrome, comprising the step of administering to said individual an amino acid sequence of SEQ ID NO:3.
A method of treating an individual for Sertoli Cell only syndrome, comprising the step of administering to said individual an amino acid sequence of SEQ ID NO:4.
Dependencies are inferred from the claim text.